Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Zenas BioPharma, Inc. ( (ZBIO) ).
On December 10, 2025, Zenas BioPharma, Inc. announced the approval of its 2026 Inducement Plan, which allows the company to grant up to 1,000,000 shares of common stock as non-statutory stock options, stock appreciation rights, restricted stock units, and other stock-based awards. This plan is designed to attract new employees or rehire former employees after a break in employment, without requiring stockholder approval as per Nasdaq Listing Rule 5635(c)(4).
The most recent analyst rating on (ZBIO) stock is a Hold with a $42.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.
Spark’s Take on ZBIO Stock
According to Spark, TipRanks’ AI Analyst, ZBIO is a Neutral.
Zenas BioPharma’s overall stock score is primarily influenced by its strong technical momentum and positive corporate events, which are offset by poor financial performance and valuation concerns. The company’s recent strategic moves in the autoimmune market provide a promising outlook, but significant financial challenges remain.
To see Spark’s full report on ZBIO stock, click here.
More about Zenas BioPharma, Inc.
Average Trading Volume: 412,470
Technical Sentiment Signal: Buy
Current Market Cap: $2.18B
Find detailed analytics on ZBIO stock on TipRanks’ Stock Analysis page.